Podcasts about Longo

Professor Matthew Longo. Longo details the geopolitical backdrop of 1989, focusing on Hungarian Prime Minister Miklós Németh. He explains Németh's clash with Romania's Ceaușescu and a pivotal, secret meeting with Gorbachev, where Németh received tacit approval to dismantle the Iron Curtain's physical border defenses. 1960S

Professor Matthew Longo. Longo shifts focus to "radical nobodies," specifically activists Ferenc and Maria, who conceived the Pan-European Picnic. He describes their audacious, naive plan to host a party at the lethal Iron Curtainborder near Sopron, intending to celebrate European togetherness and unwittingly sparking a major historical event. NOVEMBER 1961 BERLIN

Professor Matthew Longo. Longo describes the tension at the campsite where East German refugees, monitored by Stasi agents, gathered. He recounts the chaotic border breakthrough, highlighting the moral choice of Hungarian guards who allowed refugees to cross into Austria rather than shooting, marking a bloodless victory for freedom. 2016 GERMANY

Professor Matthew Longo. Reflecting on the site thirty years later, Longo discusses the philosophical implications of freedom using Isaiah Berlin and Hannah Arendt. He contrasts Western "negative liberty" with the solidarity desired by East Germans, noting how the former borderland has transformed into an unremarkable green belt. 1985 CZECH FRONTIER

Tune in here to this ​Tuesday edition of Breaking With Brett Jensen! Breaking Brett Jensen is joined in the studio by David Longo, chair of the Charlotte Regional Business Alliance and board member of Charlotte Center City Partners. Longo discusses his role on the newly formed Metropolitan Public Transit Authority. The goal of the transit authority is to ensure safety across all Charlotte Area Transit System services once the recently approved one-cent sales tax referendum goes into effect. Safety on Charlotte transit is a central theme throughout the interview. Longo emphasizes that safety and security are his top priorities and says implementing a system that supports those goals is critical. To accomplish this, Longo suggests leveraging technology to identify individuals who should not be allowed to ride the light rail or bus system. He also notes that expanded technology on the CATS system could help alert authorities to potential escalations before they become more serious issues. Listen here for all of this and more on Breaking With Brett Jensen. To be the first to hear about Breaking Brett Jensen's exclusives and more follow him on X @Brett_Jensen!See omnystudio.com/listener for privacy information.

Show notes: (0:00) Intro (0:56) Dr. Longo's surprising path from music student to aging expert (2:00) Early yeast studies and the 10x lifespan breakthrough (3:56) Launching the Fasting Mimicking Diet and supporting clinical trials (6:15) The dangers of long-term calorie restriction and yo-yo dieting (12:18) Why 12-hour fasting is safer than 16+ hours (18:22) Key differences in fasting for women (20:52) What's actually in the Fasting Mimicking Diet (23:41) How often to do it and who benefits most (28:47) Regenerating organs with stem cells and fasting (34:55) The Longevity Diet (38:11) Legumes, protein levels, and real-world advice (45:08) Fasting and cancer: what early research shows (48:15) Where to learn more from Dr. Longo (49:00) Outro   Who is Dr. Valter Longo?   Dr. Valter Longo is the Edna M. Jones Professor of Gerontology and Biological Sciences and Director of the Longevity Institute at the USC Leonard Davis School of Gerontology, a leading center for aging and disease research. Trained in biochemistry at the University of North Texas and UCLA, with postdoctoral work under longevity pioneers Roy Walford and Caleb Finch, Dr. Longo has built a multidisciplinary research career spanning genetics, immunology, endocrinology, and molecular biology. His laboratory has identified key genetic pathways that regulate aging and demonstrated how targeting these pathways can reduce disease risk and progression in both animal models and humans, including novel dietary and genetic strategies that protect healthy cells while making cancer cells more vulnerable to treatment.   Dr. Longo is widely known for developing the fasting mimicking diet, a five-day periodic dietary intervention shown in randomized clinical trials to reduce markers associated with aging and chronic disease, while promoting stem cell–based regeneration and longevity. His work has earned numerous prestigious awards, including the Glenn Award for Aging Research, and in 2018 he was named one of Time Magazine's 50 most influential people in health care. Deeply committed to public health and accessibility, Dr. Longo donates all proceeds from his bestselling books, including The Longevity Diet and Fasting Cancer, to research and education through his foundations in Milan and Los Angeles, advancing affordable strategies to prevent disease and extend healthy lifespan. Connect with Dr. Longo: Website: https://valterlongo.com/                 https://l-nutra.com/ Facebook: https://www.facebook.com/profvalterlongo/ IG: https://www.instagram.com/prof_valterlongo/   Grab a copy: https://tinyurl.com/4h4mspmt                        https://tinyurl.com/j23u989b Links and Resources: Peak Performance Life Peak Performance on Facebook Peak Performance on Instagram

Mike sits down with Lawrence Longo, a serial food and hospitality entrepreneur whose journey from hidden menu curator to restaurant empire builder has reshaped how people connect through food. Lawrence shares how his early obsession with experience over ego led him from launching Off the Menu — a community built around secret dishes and insider dining — to reviving Irv's Burgers, expanding Prince St. Pizza nationwide, and building a hospitality group that's redefining what "premium fast food" really means. They dive into the lessons learned from scaling beloved brands without losing their soul, the role of storytelling and community in hospitality, and what travel and culture have taught Lawrence about simplicity, obsession, and belonging. This episode isn't just about food — it's about the universal language of connection, the places that shape us, and the people who keep showing up for what feels real. Chapters: 00:00 – From hidden menus to hospitality visionary 05:00 – The story behind Off the Menu and food as connection 10:00 – Reviving Irv's Burgers and honoring old-school soul 15:00 – Expanding Prince St. Pizza without losing authenticity 20:00 – Scaling restaurants while keeping local roots 25:00 – Simplicity, obsession, and the power of hospitality 30:00 – Partner alignment and trusting local voices 35:00 – The community mindset behind every concept 40:00 – The travel that shaped a hospitality entrepreneur 45:00 – What it really means to build brands people love

Nicola Longo MD, PhD, and Mark Roberts, MDDrs. Longo and Roberts discuss the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at WORLDSymposium 2025 in San Diego, California on February 4th-7th 2025 and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses.The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Longo will discuss the current treatment landscape and limitations in lysosomal disorders.Nicola Longo MD, PhDWhat I want to do today, is just place gene replacement therapy within the current landscape of lysosomal storage disorder treatment therapy. Gene therapy obviously has the potential of treating lysosomal disorder to correct the root cause of lysosomal storage disorder. The gene is defective, and what happen is that you can potentially either fix the gene or bypass the lack of the genetic product. But there are already therapies that are existing and are functioning. Obviously, in many cases, the lysosomal disorder is caused by defective production of an enzyme, which is defective.We can either replace the enzyme with enzyme replacement therapy, or provide chaperone for specific mutations that retain the synthesis of the enzyme, that however is not very functional. Another avenue that it is being reported is the utilization of substrate reduction therapy. A substrate accumulates, you prevent the synthesis of the substrate to reduce the accumulation of toxic material. What we know now is that this is not enough to produce many lysosomal disorders. In many cases, the lysosomal disorder result sometime in impairment of intracellular trafficking, and sometime in the function of other organelles.At the end, it results in the activation of the macrophagic system and inflammation. Already we have some therapy acting at this level. The end result of lysosomal storage disorder, there will be cell suffering and cell death, leading to a progression of the disease, and morbidity and mortality. Now, what therapy do we have available already? Obviously, hematopoietic stem cell transplantation has been around for quite some time.It has been the same thing that we do with gene therapy, except that instead of reintroducing the gene of the subject, we place gene of a subject who is not affected of the disease. This therapy has been proven effective in cases of MPS-1 and alpha-mannosidosis. But in many cases this has to be given way before symptoms start to be affected.Enzyme replacement therapy has been around for quite some time, starting with Gaucher disease, and now that it is available for a list of diseases that are there, so it's like Fabry, Gaucher, Pompe, different types of mucopolysaccharidosis, alpha-mannosidosis, acid lipase deficiency, 1 neuronal ceroid lipofuscinosis, and Niemann-Pick type A and B.Obviously the advantage of this therapy, they give back the enzyme that it is defective. But the disadvantage that many time they cannot enter specialized areas such as the brain. There is already the second generation of enzyme replacement therapy that it is available. With this second generation, some of the newer drugs are more effective in terms of cellular uptake, or in terms of having a prolonged half-life and prolonged activity.Then there are pharmacological chaperone therapy, and the one which is FDA approved is migalastat for Fabry disease, under study is ambroxol for Gaucher disease. The disadvantage of this therapy that only a selected number of mutations respond to this therapy.Substrate reduction therapy has been introduced for Gaucher disease many years ago with miglustat, and it was followed by eliglustat. Both of them are effective, and some of them more effective than other, simply because of the fewer side effects of eliglustat as compared to miglustat. But at the same time, eliglustat does not pass the blood brain barrier.Finally, the newer agents that are already administered, N-acetyl-L-leucine and arimoclomol, both approved for Niemann-Pick type C, they act more on the downstream effect of the lysosomal storage disorder, either by stabilizing neuronal cell activity or by reducing the inflammation that is present in the brain.In the next part, Dr. Longo will discuss gene replacement therapy in lysosomal disorders.

Nicola Longo MD, PhD, and Mark Roberts, MDDrs. Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025, and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas.In this part, Doctors Roberts and Longo will discuss treatment with gene therapies.Question: Can one administer AAV-mediated gene therapy repeatedly?Mark Roberts, MDI think the traditional view would have been no. One can think of gene therapy as a silver bullet. Hopefully, it will reach its target. But if it's not effective, that bullet has been shot, the immunological response has occurred, and it means redosing, at least with that particular vector, may become difficult. But this situation is changing and evolving as we have better understanding of immunological modulation for repeat testing. We were discussing this yesterday evening, weren't we, Professor Longo?Nicola Longo MD, PhDCorrect. Basically, the current AAV-based gene therapy cannot be readministered. It is either effective, or it doesn't work. The other thing is that even though in theory, one could utilize a different AAV vector with different immunogenicity, there is many times cross-reactivity among the different adenovirus, adeno-associated viruses. Now, there are approaches in animal models in which you give a strong immune suppression to prevent the creation of the immune response against the adeno-associated virus, and at least in the animal model, it has been possible to give some of the gene therapy repeatedly.The second approach that is being tested is with gene correction therapy, in which by using an RNA guide and the CRISPR/Cas9 system delivered by lipid nanoparticles, you basically correct some of the effective genetic information. Obviously, since this is done by lipid nanoparticles and not by an AAV, the immunity that you create is really not there. You can give this one repeatedly, and in theory, it can be given more than one time. But again, you are absolutely correct. The current gene therapy cannot be given twice, and either it works or it doesn't work.Question:vWill gene-therapy-treated patients be able to go back to the standard of care or enzyme replacement therapy?Mark Roberts, MDI think when we're talking to patients about the potential benefits of gene therapy and the amelioration of the requirement to have these infusions on a regular basis of ERT, the hope is that will work, but they need to be reassured that we can potentially go back to the ERT. Gene therapy is an important treatment, but we don't know the destination of the patient at the beginning, and we have to make it available to them to go back to ERT.One of the crucial questions, of course, though, is the basis of the immunological reaction that perhaps prevented the gene therapy being effective. If it's against the viral vector, well, okay. If it's against the transgene, not great. If it's against the functional protein, that becomes more difficult. It is somewhat, I think at this time, to be fair to say to patients, think of gene therapy as a trial treatment. It is somewhat a leap of faith and an important observation, of course, for the patient community, but just be aware there may be downsides.Nicola Longo MD, PhDThey totally agree with Dr. Roberts. In general, they should be able to go back to enzyme replacement therapy if the gene therapy is not effective. However, what we are starting to appreciate is that we need to understand the immune response, not just to the enzyme replacement therapy, but also to gene therapy. What this field is doing is forcing geneticists to deal with the immune response. I feel that historically has not been dealt together. The two things need to be integrated. The advantage of the gene therapy is that the protein is produced endogenously. There should be the development of some degree of tolerance with time in the body towards the endogenous continuous production of a protein.Now, will that happen all the time? I still do not know. Again, we need to understand much better what is the integration of the immune system with the response to gene therapy in the ongoing clinical trials.

Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfessor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025, and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Longo will discuss ongoing gene therapies in lysosomal disorders.Nicola Longo MD, PhDI'm going to present to discuss some example of ongoing gene therapy for lysosomal disorder. There are gene therapy in development for both Fabry disease and some of this involve ex vivo gene therapy, many others involve systemic administration with an AAV, Gaucher disease type 1 that affect the periphery, and Gaucher disease type 2, where the replacement should occur within the central nervous system because this condition affects the brain. There is already one approved gene therapy for lysosomal disorder, which is for the early onset metachromatic leukodystrophy. This has been approved both in Europe and now even in the United States, which consists of ex vivo gene therapy with the administration of an extra gene that restore the function of the defective enzyme. Now there are many others that are ongoing for the same indication. There are gene therapy programs for GM1 and GM2 gangliosidosis, and at least one for Krabbe disease. It is important to know that some of these condition are actually included in the recommended uniform screening panel. Basically, we would have access to patients in a timely manner for some of these conditions. Then there are several gene therapy under development for the mucopolysaccharidoses, including MPS-IH, MPS-II, MPS-IIIA and MPS-IV.There are different type of lysosomal disorders, the one caused by mutation, integral membrane protein, not enzyme within the lysosome, but protein that are present on the membrane of the lysosome. This gene therapy that have been tested, it is for cystinosis, that it is caused by a defective lysosomal and for Danon disease, which is caused by a deficiency of an integral membrane part. Finally, one lysosomal disorder, which obviously seems a metabolic condition, but it is really not, is glycogen storage disease type 2 or Pompe disease, in which there is the intralysosomal accumulation of glycogen. There are several ongoing clinical trials to try to correct the problem in this condition.Now, I'm going to discuss some of the most advanced program in the lysosomal storage disorder. This include one for Fabry, which is on an accelerated approval pathway with phase 1 and 2 data, one for Gaucher disease type 1. Obviously, I'm going to discuss the one that has been already approved for metachromatic leukodystrophy. There is one for Hunter syndrome, and the difference of the one for Hunter syndrome, it is an example of the direct administration of gene therapy within the central nervous system.Finally, there is one ongoing for glycogen storage disease type 2 or Pompe disease in adult patients. In gene therapy for metachromatic leukodystrophy, it was the first gene therapy approved for lysosomal disorder in human, and this requires harvesting the CD34 cell from affected patient and then introducing the [inaudible 00:04:32] gene back in this cell, and then placing them back inside the patient again. This has been very effective in patients who were treated early, and obviously, the treatment needs to occur before there is irreversible brain damage in this patient.In the next part, Dr. Roberts and Longo will discuss treatment with gene therapies.

Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfessor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight part podcast series. This is derived from the symposium that was presented at World Symposium 2025, in San Diego, California, on February 4th through 7th, 2025, and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established, and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Longo will discuss gene replacement therapy in lysosomal disorders.Nicola Longo MD, PhDLet's go back a second to gene therapy. Gene therapy obviously has the potential of answering many of the questions that we still have open in lysosomal disorder because they could restore the activity of the lysosome pretty much in the whole body, or at least in multiple tissues. As you have seen, gene therapy can be done ex vivo where we take cells from the affected patient, we correct the gene, or we put an extra gene that it is functional. Then we put them back by doing a bone marrow transplant, basically creating space for the cells that have been genetically modified to correct the lysosomal defect. The biggest approach this is done usually by lentiviruses that they integrate inside the genome.

Nicola Longo MD, PhD, and Mark Roberts, MDNicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfesor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discuss the current status of gene therapies in rare neuromuscular disorders in this 8-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th-7th 2025 and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses.The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Roberts will discuss immune responses and other safety concerns related to gene therapies.Mark Roberts, MDUndoubtedly, the immune system is a major issue in these patients. It would be fantastic if we could immunotolerize our patients and indeed prevent the rejection of the therapy. We've talked about the fact that these are viral vectors and of course there may be high seroprevalence of antibodies to these viral vectors, and it's very important in the pre-screening of patients who might be eligible to understand that at the beginning. These of course can have developed over the years and of course can be part of immunological memory and therefore extremely difficult and probably impractical to actually shift.On giving the treatment though as I think we're all aware there is this problem of the innate immunity and potential therefore for acute toxicities and then a learned or adaptive response with cytotoxic T cells and antibodies which may of course become high tighter neutralizing antibodies and potentially antibodies not only against the viral vector, even the functional protein, even the transgene are all theoretical possibilities with time. The capsid, the transgene, and even the protein product can all potentially induce an immunological event. Of course, all of these would lead to both potential patient changes and then a lack of efficacy of the treatment.Indeed, there have been some serious and indeed fatal problems in the gene therapy development program as I think we're all aware. Though many of these are thankfully been overcome. Spinal muscular atrophy has a gene therapy which is licensed, but there were early patients who actually had significant problems. A patient of just 6 months of age who developed kidney failure, two other patients who actually developed liver failure.In Duchenne muscular dystrophy, a very common condition, again there were significant issues and crucially in these patients who all have cardiomyopathy, it was heart failure and cardiac arrest that were big concerns and pulmonary edema and this was seen even with a CRISPR-based technology and is perhaps is best known but has been addressed the excellent myotubular myopathy patients, four patients died and crucially quite a long time after the gene therapy emphasizing the need to monitor these patients extremely carefully and these patients died of cholestatic liver failure albeit that they had a degree of liver dysfunction.That's changed our screening of course of patients, we're now all looking in myotubular patients for liver involvement and Rett syndrome as well. Now these immunoprophylaxis treatment regimes to hopefully try and reduce the immunological reaction against the gene are certainly evolving.This is just a summary of some of the other immunosuppressive regimes used in other disorders, for example, spinal muscular atrophy, but Pompe and MPS as examples of LSDs. Certainly these regimes will continue to evolve and are going to be very important in seeking to make sure that these treatments are effective. It reminds me somewhat of what's happened with enzyme replacement therapy that the use of these immunological strategies in infants has revolutionized the utility of those treatments in early patients.In the next part, Dr. Roberts will discuss lessons learned from gene therapy trials.

Nicola Longo MD, PhD, and Mark Roberts, MDNicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfessor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs.Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025 and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas.In this part, Dr. Roberts will discuss lessons learned from gene therapy trials.Mark Roberts, MDWhen we think about the challenges of actually doing clinical trials with these gene therapies, there's a huge development stage in terms of picking the right viral vector with the right surface receptor. That's a major piece of work. That can often take years. The preclinical work is obviously very important as indeed is understanding the natural history because it's really not practical to do placebo-controlled trials of gene therapies.In contrast to other studies, when we turn to phase 1 and phase 2, you'll notice that the patient numbers are often quite small. One is having to think carefully about surrogate measurements of response. Especially when in phase 3 studies, we may be thinking about withdrawing the existing, for example, enzyme replacement therapy because we believe the gene therapy will then be effective.That's just a few snapshots of where we've come and there's a lot more work to be done.In the next part, Dr. Longo will discuss the current treatment landscape and limitations in lysosomal disorders.

Nicola Longo MD, PhD, and Mark Roberts, MD Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfesor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discuss the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025 and is intended for healthcare professionals only. This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses. The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice.The contents of this presentation do not constitute an endorsement of any product or indication by Astellas. In this part, Dr. Roberts will discuss vectors, different strategies, modes of administration and targets in gene replacement therapies.Mark Roberts, MDNow in the broader sense, gene replacement therapy seeks to actually deliver genetic material directly into the host cell to influence gene expression. In the most simple idea, one of course has a vector, this is most commonly but not exclusively a virus, which can then be given intravenously for example, and can hope to potentially correct the condition within the individual cells using novel transgenes. Suitable candidate conditions for this as examples of genetic conditions are now well understood. And crucially, this applies not only towards some more recessive, but dominant and even accident conditions.Across the piece, one can see for example, mitochondrial problems, spinal muscular atrophy as is well known, X-linked myotubular myopathy, Duchenne muscular dystrophy, a very common condition affecting one in 3000 male individuals, Pompe disease of course, an important focus of the meeting here, but other very common conditions, for example, cystic fibrosis, immunological conditions and perhaps obviously very crucial in early work on gene therapy, hemophilia.Let's now think about the approaches to gene therapy. One can seek to work at the DNA level and gene replacement. In essence, one is trying to put a new transgene through into the nucleus that will ultimately be transcribed and translated and produce the important functional protein that is lost. Gene editing which is a very exciting new technology or CRISPR technology actually seeks to actually modify in vivo the actual mutations that are responsible for the pathogenic production of abnormal proteins and correcting these and actually producing a more normalized protein.But of course there are also RNA approaches where one seeks to actually repair the mRNA transcripts copied from the mutated gene. For example, this may be a novel approach that could be extremely useful in myotonic dystrophy, a multisystem condition. When we talk about the viral vectors, predominantly we're talking about viruses. Those such as adenoviruses and AAV viruses which have the virtue of not integrating into the host genome or at least not in a large amount, and those which deliberately seek to integrate into host genome such as retroviral or lentiviral systems that may be particularly useful for ex vivo systems.There are of course other ways to get genetic payloads into the nucleus, various polymers, nanoparticles and even cell penetrating peptides. Nanoparticles in particular is certainly on the ascendant. That being said, in a recent review of the clinical trials in gene therapy, it was certainly the viral vectors that stood out both in direct gene replacement with lentivirus and AAV, but also actually as delivery systems, for example, for gene editing. An example of what one is seeking to do with AAV, so of course one seeking to remove the native DNA, insert the new transgene directly into the vector and of course keen to make sure that there's a high transmission into the capsid producing a recombinant AAV, which then can be given as a treatment and hopefully produce a therapeutic increase in the functional protein that is deficit in the disorder.In the next part, Dr. Roberts will discuss immune responses and other safety concerns related to gene therapies.

When Lawrence Longo launched the Off the Menu app, he was not envisioning becoming one of the most prolific restaurateurs in Los Angeles. Yet a decade later, that's exactly where we are. Lawrence is responsible for the birth of Prince St. Pizza in Los Angeles, rescuing beloved stalwart Irv's Burgers, launching Tacos 1986 & even pioneering the smashburger craze with Burgers Never Say Die. Truly a fascinating character with a unique & fun origin story.

Nicola Longo MD, PhDProfessor and Vice Chair of Human Genetics,Allen and Charlotte Ginsburg Chair in Precision Genomic Medicine,Division of Clinical Genetics, Department of Human Genetics,University of California at Los Angeles (UCLA), Los Angeles, CA, USAMark Roberts, MDProfessor and Consultant Neurologist,University of Manchester, Manchester, UKResearch Lead for Adult Metabolic Medicine at Salford Care Organisation, Manchester, UKDrs. Longo and Roberts discussed the current status of gene therapies in rare neuromuscular disorders in this eight-part podcast series. This is derived from the symposium that was presented at World Symposium 2025 in San Diego, California on February 4th through 7th, 2025, and is intended for healthcare professionals only.This podcast includes information about investigational compounds that do not yet have a regulatory approval or authorization for a specific indication. The safety and efficacy of the agents under investigation have not been established, and contents of this podcast shall not be used in any manner to directly or indirectly promote or sell the product for unapproved uses.The views, thoughts, and opinions expressed in this presentation belong solely to the author and are subject to change without notice. The contents of this presentation do not constitute an endorsement of any product or indication by Astellas.In this part, Dr. Roberts will discuss lysosomal disorders and the potential for gene therapies.Mark Roberts, MDI'm going to give an overview of what is gene therapy, emphasizing the current challenges and the development issues and needs that there will be as we try and enable gene therapy for our patients, particularly those with lysosomal storage disorders.I'm going to try and make a case for why lysosomal storage disorders are an extremely good group of conditions for the potential benefits of gene modifying therapies. Firstly, whilst we all recognize that these conditions are inherently individually rare, they're certainly severe. Collectively, with over 70 LSD disorders, 1 in 5,000 may be afflicted by these conditions ultimately in their life and can be detected, for example, by newborn screening programs.Secondly, there's certainly a significant clinical burden with these patients with the current standard of care, so a large unmet need exists. Existing enzyme replacement therapies have undoubtedly changed the natural history of many of these conditions, but there are limitations and often initial benefits and later deteriorations.Unfortunately, for most lysosomal storage disorders, it's only symptomatic treatments and indeed, care that is available for these patients with no specific treatment. Thirdly, these conditions are extremely well-characterized, monogenic singleton and problems of inborn errors of metabolism. We know the functional protein that is deficient in these conditions. Because of that, and knowing that these are critical for lysosomal function, and using preclinical models, we can model the potential benefits of gene therapies very well in a number of systems, including, of course, soon, muscle chip experiments as well.Finally, with these conditions, they may potentially be really useful targets whilst not perhaps curing the condition, at least ameliorating the phenotype, and enabling the addition of other treatments as well, potentially. I've noted, some of these therapies can be directly delivered to certain tissues, so muscle tissue, which is my main interest, but also, crucially, the central nervous system, which is very important when we consider ameliorated phenotypes, for example, treated by enzyme replacement therapy, but where the children who become the adults have significant learning disability as a major component to their problems.In the next part, Dr. Roberts will discuss vectors, different strategies, modes of administration, and targets in gene replacement therapies.

Il coreografo e vicedirettore artistico del Balletto di Roma, Valerio Longo, torna al FIND 2025 con una masterclass formativa e uno spettacolo che unisce linguaggi, visioni e nuove generazioni della danza. Il FIND – Festival Internazionale Nuova Danza 2025 accoglie una delle voci più significative della scena contemporanea italiana: Valerio Longo, coreografo, docente e vicedirettore artistico del Balletto di Roma. Sabato 22 novembre Longo guiderà la masterclass Spiritual Body Experience presso la Scuola di Danza Assunta Pittaluga, un appuntamento atteso da danzatori, studenti e appassionati. La lezione approfondisce la relazione tra corpo, spazio, ritmo ed emozione. Longo invita i partecipanti a un viaggio interiore, trasformando il movimento in strumento di esplorazione personale. Equilibrio, peso, articolazioni e dinamica non sono solo elementi tecnici, ma porte d'accesso alla consapevolezza artistica. Dal corpo alla visione: la danza come esperienza spirituale La Spiritual Body Experience nasce dall'idea che il gesto non sia soltanto esecuzione, ma un territorio sensibile in cui disciplina e libertà convivono. Longo sottolinea come lo studio costante, la perseveranza e l'ascolto interiore conducano a una forma di autenticità scenica, capace di rivelare la parte più profonda del danzatore. In questo senso, la passione originaria diventa bussola, memoria e motore creativo. DislocAzioni in Danza: il Balletto di Roma tra tradizione e nuove estetiche Sempre sabato 22 novembre, a seguire, la giornata prosegue a Sa Manifattura – Sala Officine con lo spettacolo DislocAzioni in Danza, firmato Balletto di Roma. Diretto da Francesca Magnini, il lavoro presenta coreografie di Marcello Giovani, Martina Licciardo e Valerio Longo, interpretate da Paolo Barbonaglia, Alessio Di Traglia, Martina Licciardo e Ainhoa Segrera. Lo spettacolo è una lente sulle molteplici identità del movimento: dalla danza accademica alle urban dance, fino ai linguaggi performativi contemporanei. È un incontro fertile tra spazio, corpo e spettatore, una fusione spontanea di poetiche e generazioni.

Originalmente, as seis partes que formam o Oratório de Natal (BWV 248), de Johann Sebastian Bach - composto em Leipzig para celebrar o Natal de 1734 -, não foram apresentadas todas na mesma ocasião. Cada uma delas foi executada num dia diferente, de acordo com o calendário litúrgico cristão referente às festas de Natal. A primeira parte foi exibida no primeiro dia de Natal, dia 25. A segunda, no segundo dia de Natal, dia 26. E a terceira, no terceiro dia de Natal, dia 27. A quarta parte foi destinada ao dia de Ano Novo, 1º de janeiro, data da Festa da Circuncisão de Jesus. A quinta parte foi apresentada no primeiro domingo após o Ano Novo. E a sexta parte foi executada na Festa da Epifania, 6 de janeiro, que lembra o batismo de Jesus e a visita dos reis do Oriente, concluindo os festejos de Natal. Essas seis partes estão sendo ouvidas em Manhã com Bach ao longo de seis programas. Nesta edição, o podcast exibe a quarta parte. O programa traz ainda o Concerto de Brandemburgo Número 5 em Ré Maior (BWV 1050). Ouça o podcast no link acima. Este podcast reproduz o programa Manhã com Bach, da Rádio USP (93,7 MHz), transmitido nos dias 13 e 14 de dezembro de 2025. Dedicado à divulgação da música do compositor alemão Johann Sebastian Bach (1685-1750), Manhã com Bach vai ao ar pela Rádio USP (93,7 MHz) sempre aos sábados, às 9 horas, com reapresentação no domingo, também às 9 horas, inclusive via internet, através do site da emissora. Às segundas-feiras ele é publicado em formato de podcast no site do Jornal da USP. As edições anteriores do podcast Manhã com Bach estão disponíveis neste link.

Neste episódio emocionante, Carol Zaine, Adão Casares e Mari Cruz, diretores da APP, batem um papo muito interessante com Daniela Pereira, da Unilever. Foi uma conversa aprofundada sobre o presente e o futuro da mídia: do papel das marcas na construção de narrativas ao impacto das novas tecnologias no comportamento do consumidor.Apresentação: Carol Zaine (APP Brasil, Vert.se, UnaSports Lab)Coapresentação: Adão Casares (APP Brasil, Crisálida)Produção: Eduardo Correia, Mariana CruzGravação, Montagem e Edição: Fibra.ag, GOLiVEApoio: Globo, SBT, Record, Vert.se , Fibra.agPara saber mais sobre a APP Brasil, acesse http://www.appbrasil.org.br/

_

Nesta edição do "Viaje na CBN", o comentarista Edson Ruy traz como destaque a notícia que o recorde de voo comercial mais longo do mundo sem paradas poderá ser superado por um novo avião: o A350-1000ULR, da fabricante europeia Airbus. A aeronave poderá voar por até 22 horas seguidas, sem a necessidade de parada, informou a companhia aérea australiana Qantas.Segundo informações do portal "G1", atualmente, o voo mais longo do mundo é operado pela Singapore Airlines e dura cerca de 18 horas, ligando Nova York a Singapura, segundo o Flightradar24, site que monitora voos pelo mundo. A Qantas encomendou 12 aviões desse modelo e divulgou novas imagens da primeira unidade, que deve ficar pronta em 2026. O voo comercial de estreia está previsto para o primeiro semestre de 2027.Ainda, de acordo com a reportagem, o investimento faz parte do que a empresa chamou de Projeto Sunrise ("nascer do Sol"). Ele ganhou esse nome porque, devido à diferença do fuso horário entre a Austrália e o restante do mundo, os passageiros poderão ver o nascer do sol duas vezes nos voos mais longos.

In occasione della Giornata Internazionale delle Persone con Disabilità Parliamo di lavoro con Annagrazia Bonito - che si occupa di selezione e placement di talenti appartenenti alle categorie protette per Grafton, società di ricerca e selezione di Gi Group Holding - e con Haydée Longo, avvocata specializzata sui temi di inclusione e diritti umani e fondatrice della Federazione Disability Management ("Fe.D.Man.").

No episódio de hoje conversamos sobre o texto “Do que eu não abriria mão” do Ogden e, a partir do texto, nos propusemos a responder do que nós não abriríamos mão. Esperamos que essa pergunta chegue a cada um de vocês como uma provocação para fazer pensar. Você já comeu bobô frito? Nesse episódio, tivemos o prazer de degustar e contar a história desse doce típico de São Tomé e Príncipe. Quer conhecer também? Entre no https://www.instagram.com/bobofrito.oficial e peça o seu!Quer estar por dentro de todos os eventos, cursos e muito mais que o IEP realiza? Entre no https://www.instagram.com/iep_rp e fique por dentro. Styling: https://www.instagram.com/cordui.ferborgesTenha sua marca registrada pela https://www.instagram.com/sabiamarcasepatentes . Com o cupom AudioLongoSabiá10 você tem 10% de desconto!Apoie o Desculpa o Áudio Longo: https://www.catarse.me/desculpaoaudiolongo ou PIX: desculpaoaudiolongo@gmail.com

Zozeer immers heeft God de wereld liefgehad, dat Hij zijn eniggeboren Zoon heeft gegeven, opdat al wie in Hem gelooft niet verloren zal gaan, maar eeuwig leven zal hebben. – Joh 3.16 We gaan op bezoek bij twee personen die op een wonderlijke wijze uit een wereld van duistere en occulte krachten zijn kunnen treden: […]

After nearly 20 years at the top, Football Fern Annalie Longo is hanging up her boots after tomorrow's game against Australia. Longo made her senior debut as a 15-year-old and has played more than 140 times for the Football Ferns including at five World Cups and four Olympic Games. The timing of the midfielder's decision to retire was part of New Zealand Football's planning towards the 2027 Football World Cup. Sports reporter Felicity Reid spoke to Lisa Owen.

Renee Fitton is a registered dietitian, entrepreneur, and expert in nutrition, longevity, and healthcare innovation. She specializes in fasting-mimicking diets, cellular renewal, and bridging scientific research with practical health applications.  She is the Director of Education & Healthcare Sales at ProLon, where she develops sales strategies, educates healthcare practitioners on nutrition and longevity science, and promotes fasting-mimicking diets. She also serves as a Medical Science Liaison (since April 2023). 0.00:    Renee's background as a longevity dietician 8.00:    The power of diet 10.00:  The power of Fasting 14.00:  Why Fasting Mimicking diets are so powerful (Dr. Longo) 21.00: How Fasting Mimicking has insignificant muscle loss 26.00:  How to eat healthy 31.00:  Intermittent fasting (AM versus PM) 41.00: Ideal Evening Meal before athletic events 45.00:  Supporting autophagy and cellular cleanup only in longer fasts 50.00:  Coming off a longer fast/ fasting mimicking diet 56.00:  Meat for athletic performance vs longevity 1.01.00: Different protein powder sources (and L-Protein) Renee on IG: @fitonnutrition Prolon website: https://prolonlife.com/ Until next time, love and good vibes.  Podcast Website: https://enterthelionheart.com/ Check out the latest episode here: Apple Podcast: https://podcasts.apple.com/us/podcast/enter-the-lionheart/id1554904704 Spotify: https://open.spotify.com/show/4tD7VvMUvnOgChoNYShbcI

Maioria dos efeitos colaterais do botox são leves e passageiros; agora, cientistas estão investigando também se uso a longo prazo pode trazer efeitos negativos.

In this episode of Getting to Know KRA, we are joined by Program Director Mike Longo, as he highlights how his decades of experience in workforce development inform the way his team meets job seekers with empathy, structure, and personalized support. You'll learn how career coaches, business services staff, and community partners work together to make the OhioMeansJobs centers in Summit and Medina counties accessible, welcoming, and effective for anyone seeking employment. From innovative outreach tools to real success stories that show the impact of strong relationships, this episode offers a behind-the-scenes understanding of how KRA's values, people, and processes come together to support both job seekers and employers across the region.

We love bringing the best people in Baltimore together. There's been a magazine story on the wall at Koco's Pub for years that compares the Marcella Knight's jumbo crab cake to the smoked version from our friend Chef Nancy Longo of Pierpoint. So, Nestor brought them together in Lauraville on the Maryland Crab Cake Tour for foodie fun. The post Chef Nancy Longo of Pierpoint and Marcella Knight meet at Koco's Pub to share love and lore of the Maryland crab cake legacy first appeared on Baltimore Positive WNST.

In this first instalment of a two-part exclusive, The Food Professor Podcast sits down in person with Michael Medline, (now) former President and CEO of Empire Company Limited and Sobeys, in what serendipitously became his last official interview before news broke of his transition to lead The Woodbridge Company. Michael offers a rare, deeply personal look at his eight-plus-year tenure transforming one of Canada's largest retailers. He recounts stepping into the role in 2017, reshaping strategy, modernizing systems, and fostering a culture built on values, innovation, and operational excellence.Michael reflects on navigating the massive disruptions of recent years—from COVID-19 to global trade volatility and technological upheaval—while maintaining a clear North Star for the organisation. He shares insights on revitalizing store formats, strengthening private-label programs, and embracing data transformation and automation to sharpen competitiveness. The conversation also explores the bold acquisitions of Farm Boy and Longo's, discussing trust, partnership, culture, and why collaborative integration—not assimilation—is essential to preserving what makes independent banners special.He also speaks candidly about leadership: prioritizing people, resisting micromanagement, nurturing talent, and ensuring a national grocer performs as one unified organisation rather than fragmented regional fiefdoms. Medline's reflections on turning around the Safeway acquisition, advancing omnichannel capabilities through Voilà, and pushing Empire's innovation agenda offer invaluable lessons for retail leaders navigating rapid change.The episode also features a wide-ranging news conversation with Sylvain and Michael. They break down meat-industry dynamics on both sides of the Canada–U.S. border, including beef supply challenges, oligopoly concerns, and the impact of interprovincial trade barriers on Canadian prices. The hosts also explore the “protein orphan” trend driving increased chicken consumption—and the resulting supply management shortfalls—plus the social-media-fuelled surge in cottage cheese demand.Additional segments highlight CFIA's quietly formed task force responding to U.S. regulatory instability, early snowfall's potential impact on holiday shopping, and the growing disconnect between global climate COP events and the real-world policy outcomes they aim to influence.  The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

Nelson Rodrigues está desde janeiro na Ucrânia, onde ataques recentes têm afetado o desenvolvimento das crianças; agência promove reconstrução de serviços e mantém bem-estar infantil como prioridade máxima.

O episódio apresenta um projeto que une esses três pilares, os Escritórios Verdes 2.0 da JBS, em curso tanto na Amazônia quanto no Cerrado brasileiro. Liège Correia e Silva, diretora de sustentabilidade da companhia, comenta como a iniciativa transforma, na prática, o dia a dia dos pequenos pecuaristas. Muitos desses produtores enfrentam desafios históricos de acesso a crédito, tecnologia e regularização ambiental. O projeto ajuda a superar essas barreiras e a incluir esses produtores na nova economia de baixo carbono. A apresentação é do jornalista Eduardo Geraque, com produção do Estadão Blue Studio, com patrocínio da JBS. See omnystudio.com/listener for privacy information.

Arritmias genéticas estão cada vez mais presentes na prática clínica — saber reconhecer os padrões, principais sintomas e quando solicitar teste genético é essencial.Neste episódio, Raquel Rios e William Batah recebem Dra. Luciana Sacilotto, referência nacional em arritmias e genética cardiovascular, para uma revisão didática e atual das principais síndromes arrítmicas genéticas.O que você vai ouvir (preencha os tempos depois): - Conceito e importância das cardiopatias geneticamente determinadas - História familiar, quando suspeitar e como indicar o teste genético - Síndrome de Brugada — padrão ECG, gatilhos, estratificação e conduta - Cardiopatia arritmogênica — novos critérios de Pádua, papel da RMC e do exercício - QT longo e QT curto — diferenciação, manejo e orientações familiares - Taquicardia ventricular polimórfica catecolaminérgica (CPVT) — diagnóstico e tratamento- Outras entidades: Síndrome da repolarização precoce, miocardiopatias genéticas e o papel da autópsia molecular. Além disso, entenda como interpretar testes genéticos, lidar com VOUS e conduzir testagem em cascata. Por que ouvir: se você atende síncope, morte súbita ou arritmias “sem causa aparente”, este episódio traz um guia completo para reconhecer padrões genéticos, evitar armadilhas diagnósticas e aplicar a genética de forma prática e responsável.Ouça agora no Spotify/YouTube e compartilhe com colegas que lidam com arritmias complexas — este é daqueles episódios que viram referência.Palavras-chave (SEO): arritmias genéticas, cardiopatias geneticamente determinadas, síndrome de Brugada, cardiopatia arritmogênica, QT longo, QT curto, TVPC, repolarização precoce, genética cardiovascular, VOUS, painel genético, morte súbita. _______________Assine agora! Revisões didáticas de Cardiologia, semanalmente na DozeNews PRIME: a maneira mais leve e rápida de se manter atualizado(a), através do link dozeporoito.com/prime

O Presidente da República tinha anunciado, no verão, uma avaliação da ministra da Saúde. Fez-se esperar e a intervenção só chegou no outono. Censurou a falta de estratégia para o Serviço Nacional de Saúde e pediu um acordo de regime. No dia seguinte, foi Pedro Passos Coelho a pedir uma visão mais a longo prazo das decisões políticas, se possível com acordos alargados. As intervenções de Marcelo e de Passos são o ponto de partida para a Comissão Política desta semana em que falamos de avisos e pedidos de acordo, mas também de saúde e da respetiva ministra. Conversam o comissário residente, Vítor Matos, a coordenadora da secção de Política, Liliana Valente, e a jornalista Paula Caeiro Varela, que acompanha o PSD e o Governo.See omnystudio.com/listener for privacy information.

In this episode of Catechesis, Fr Des talks about the life of St. Bartolo Longo Italian Lawyer and ex-Satanic priest and how the Rosary and a devotion to Our Lady lead his to rise out of the despair of his satanism and lead him along the path to sanctity. To listen to more Catechesis episodes […] L'articolo Catechesis – Fr Des The story of St. Bartolo Longo – Ex Satanist turned saint. proviene da Radio Maria.

Nic Longo & Jeff Bartley from The Patrick Leahy Burlington International Airport, join Anthony & Dan to give an update.

Combinação de demandas fortes, com exportação em alta , festas de final de ano e oferta mais enxuta de animais deve ajustar mercado do boi

Confira o Fechamento de Mercado desta segunda- feira (03)

Just this past Sunday, on October 19, 2025 – the 29th Sunday in Ordinary Time – Pope Leo XIV canonized seven new Saints of the Catholic Church including an Italian lawyer who renounced Satanism and his involvement in the occult and eventually became “an apostle of the Rosary.” Join us for Open Line Tuesday with Fr. Wade Menezes.

Reflexionemos junto con el Padre Flecha sobre la canonización de los siete nuevos santos que canonizó S.S. Papa León XIV y meditemos a fondo la palabra.

Send us a textA fallen seeker becomes a builder of hope as we trace Blessed Bartolo Longo's path from occult rites to a life consecrated to Mary and the rosary. We share how prayer, confession, and community rebuilt a soul and revived Pompeii with a living devotion.• early life in Brindisi and the loss that shaped him• university restlessness and the pull of secularism• descent into spiritism and satanic priesthood• a mother's rosary and hidden intercession• meeting Fr Alberto Radente and the counsel to return• confession, Eucharist, and a slow, steady conversion• consecration to Mary and the rosary promise• founding the Rosary brotherhood and restoring a chapel• miracles at Pompeii and documented testimonies• schools, orphan care, and a culture of prayer• lasting legacy and why no soul is beyond mercyBe sure to look at the description for special offerVisit our site and start your own story of faith todayOpen by Steve Bailey Support the show

Impresionante conversión del gran promotor del Rosario!

Once a priest of Satan, soon-to-be saint Bartolo Longo's life became a powerful testament to the mercy of God and the intercession of the Blessed Mother. In this episode of Fatima Today, Barb Ernster and Katie Moran share his dramatic journey from darkness into light — how the Rosary, a Dominican priest, and a devoted Sister led him back to the Catholic faith. Discover how Bartolo Longo spent the rest of his life making reparation, spreading devotion to the Rosary, and inspiring Pope John Paul II to establish the Luminous Mysteries.    

Send us a textHave you ever wondered what happens inside your body when you don't eat for a while — when you give yourself space between meals? In this week's episode of Project Weight Loss, we explore that quiet magic with the story of Nobel Laureate Maester Yoshinori Ohsumi, whose discovery of autophagy — the body's natural process of self-cleaning and renewal — changed how we understand health, vitality, and longevity. From his humble lab in Japan to the moment he glimpsed a new world under the microscope, Ohsumi's curiosity reveals how our bodies are wired to restore themselves, especially in moments of pause.We'll talk about how autophagy connects to fasting, weight management, brain health, and aging — and why giving your body a little space to “dine in” can make such a difference. You'll hear about Ohsumi's groundbreaking experiments, his partnership with his wife and collaborator Mariko Ohsumi, and how their discoveries invite us to see self-renewal as a natural rhythm of life. I'll also link this episode to my earlier one on the Blue Zones — where long-living communities show us what it means to live in harmony with our biology. Listen in, reflect, and maybe even give your body that gentle reset it's been asking for.Quote of the Week:“We are wired for feast and famine, not feast, feast, feast.” — Dr. Jason FungListen to my related episode: The Blue Zones: The Secrets to Living Citations1.    Ohsumi, Y. (2014). Historical landmarks of autophagy research. Cell Research, 24(1), 9–23. https://doi.org/10.1038/cr.2013.1692.    Mizushima, N., & Ohsumi, Y. (2002). Autophagy: Molecular machinery for self-eating. Cell, 120(4), 639–652.3.    Kaushik, S., & Cuervo, A. M. (2018). The coming of age of chaperone-mediated autophagy. Nature Reviews Molecular Cell Biology, 19(6), 365–381.4.    Madeo, F., Zimmermann, A., Maiuri, M. C., & Kroemer, G. (2015). Essential role for autophagy in life span extension. Journal of Clinical Investigation, 125(1), 85–93.5.    Longo, V. D., & Panda, S. (2016). Fasting, circadian rhythms, and time-restricted feeding in healthy lifespan.Cell Metabolism, 23(6), 1048–1059.6.    Fung, J. (2016). The Obesity Code: Unlocking the Secrets of Weight Loss. Greystone Books.Let's go, let's get it done. Get more information at: http://projectweightloss.org

Send us a textBrodie Longo is a young organizer and director of the Northeast Ohio chapter of Beyond Plastics. This grassroots organization works to combat plastic pollution and the use of single-use plastics through education and activism. In this episode, Brodie speaks about what it's been like starting a local Beyond Plastics chapter and how, at just 23 years old, he found himself leading in ways he did not expect. Together with his steering committee and volunteers, Brodie is building momentum against single-use plastic, from hosting nurdle patrols and beach cleanups to venue recycling and advocating for policy and legislative change. Hear Brodie's tips for reducing your exposure to microplastic pollution and how to join meetings, find resources, and get involved with this newly formed organization. Our Guest:Brodie Longo - Director, NEO Chapter of Beyond Plastics brodielongo@yahoo.comResources:  Beyond Plastics National OrganizationThe Problem with Plastic by Judith Enck Follow Beyond Plastics on FacebookSupport the showSupport Eco Speaks CLE Follow us: https://www.facebook.com/ecospeaksclehttps://www.instagram.com/ecospeakscleContact us:hello@ecospeakscle.com

Become a Spiritual Mentor!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Today's transcript⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. We depend on donations from exceptional listeners like you. To donate, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠click here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Daily Rosary Meditations is now an app! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Click here for more info.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠To find out more about The Movement and enroll: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.schooloffaith.com/membership⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Prayer requests⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Subscribe by email⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Download our app⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Donate⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Debbie Longo is an executive behavioral coach, entrepreneur, and founder of Life In Bloom NY, a consulting firm that transforms leadership performance and workplace culture through strategic behavioral change. With over 20 years of experience in human resources, leadership development, and behavioral strategy, Debbie works with executives and business owners to identify and shift the […]

Send us a textIn this episode of Deconstructing Comp, Yvonne and Rafael talk to Paolo Longo, a claimant attorney based in Florida, to explore the realities of representing injured workers, especially first responders. Paolo shares how his career path led him from the state attorney's office to becoming a dedicated advocate for employees navigating the workers' compensation system.He explains the unique legal protections and presumptions that apply to Florida's firefighters, police officers, and other first responders, particularly around heart disease, hypertension, and other conditions presumed to be job-related. Paolo also highlights the burden-shifting process that makes these cases unique, and why communication and education are at the heart of effective advocacy.A powerful part of the discussion centers on the fears and concerns first responders face after an injury. Paolo notes that the first question nearly every client asks is: “Am I going to lose my job?” Beyond that, they worry about whether they'll ever return to work, finish their careers, or continue providing for their families. These uncertainties, coupled with a lack of clear understanding of the claims process, make strong legal guidance and compassionate communication for injured workers essential.Another key legal point Paolo discusses is the “120-day rule.” While its meaning varies by state, in Florida, the focus of Paolo's practice, it sets the timeframe for an employer or insurance carrier to decide on a claim. Once an employer begins providing benefits, they have 120 days to either deny the claim or continue paying benefits. If they don't issue a denial within that period, the claim becomes compensable by law, unless the employer can later prove new “material facts” that weren't discoverable during the initial investigation.This rule is critical because it can determine the outcome of a case, whether benefits continue, or whether a carrier can still attempt to deny responsibility for an injury. Paolo explains how this plays out in practice and why it's such a pivotal part of representing injured workers in Florida.From candid reflections on the challenges of the system to insights on what truly makes a difference for injured workers, this conversation offers a rare look at the claimant's side of workers' compensation. ¡Muchas Gracias! Thank you for listening. We would appreciate you sharing our podcast with your friends on social media. Find Yvonne and Rafael on Linked In or follow us on Twitter @deconstructcomp

Forget boring franchises. This is the FUN one.